In the third activity of this CME Outfitters podcast series on gynecologic cancers, expert faculty will present and discuss the very latest research on treatment of endometrial cancer, including strategies that utilize molecular testing and ICI therapies.
In this CME Outfitters recorded symposium led by a multi-disciplinary panel of UC experts, clinicians will learn about the changes happening in the UC treatment landscape, which treatments may offer patients with UC a higher quality of life, and which UC treatments have significant long-term benefit, thus optimizing access to the best treatments available to patients in different stages of disease.
In the second activity of this CME Outfitters podcast series on gynecologic cancers, Drs. Richard Penson and Matthew Powell will present and discuss the very latest research on emerging treatment options for EC.
In the first activity of this CME Outfitters podcast series on gynecologic cancers, expert faculty will present and discuss the very latest research on maintenance treatment of EC and how to assess its value for newly diagnosed patients and those with recurrent EC.
Immune checkpoint inhibitors (ICIs), PARP inhibitors, VEGF inhibitors, kinase inhibitors, and chemotherapy are all being used in various combinations for the treatment of endometrial and ovarian cancers. As these new combinations seek to further improve and enhance the efficacy of treatment, the risk of AEs increases. During this informational podcast, Dr. Richard Penson and Ms. Jennifer Filipi will educate clinicians on the prevention, mitigation, and management of AEs that arise from these new combination regimens.
Data from recent clinical trials for first-line combination options using immunotherapies for ovarian cancer (OC) can be challenging for clinicians with no experience selecting patients for combinatorial treatment approaches or using combination therapies for their patients. During this podcast, Drs. Richard Penson and Ramez Eskander will educate clinicians on the use of immune checkpoint inhibitors for the treatment of OC and the use of biomarker analyses to optimize patient selection.
